AU2018260535B2 - Small organic molecules for use in the treatment of neuroinflammatory disorders - Google Patents

Small organic molecules for use in the treatment of neuroinflammatory disorders Download PDF

Info

Publication number
AU2018260535B2
AU2018260535B2 AU2018260535A AU2018260535A AU2018260535B2 AU 2018260535 B2 AU2018260535 B2 AU 2018260535B2 AU 2018260535 A AU2018260535 A AU 2018260535A AU 2018260535 A AU2018260535 A AU 2018260535A AU 2018260535 B2 AU2018260535 B2 AU 2018260535B2
Authority
AU
Australia
Prior art keywords
kgbw
bmp
group
vehicle
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018260535A
Other languages
English (en)
Other versions
AU2018260535A1 (en
Inventor
Karin Bernadet Fainberg
Arnon KARNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Original Assignee
Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center filed Critical Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Publication of AU2018260535A1 publication Critical patent/AU2018260535A1/en
Application granted granted Critical
Publication of AU2018260535B2 publication Critical patent/AU2018260535B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2018260535A 2017-04-26 2018-04-26 Small organic molecules for use in the treatment of neuroinflammatory disorders Active AU2018260535B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL251949A IL251949A0 (en) 2017-04-26 2017-04-26 Small organic molecules for use in the treatment of neuro-inflammatory diseases
IL251949 2017-04-26
PCT/IL2018/050463 WO2018198123A1 (en) 2017-04-26 2018-04-26 Small organic molecules for use in the treatment of neuroinflammatory disorders

Publications (2)

Publication Number Publication Date
AU2018260535A1 AU2018260535A1 (en) 2019-10-31
AU2018260535B2 true AU2018260535B2 (en) 2023-09-28

Family

ID=62454780

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018260535A Active AU2018260535B2 (en) 2017-04-26 2018-04-26 Small organic molecules for use in the treatment of neuroinflammatory disorders

Country Status (9)

Country Link
US (2) US11103479B2 (https=)
EP (1) EP3615022B1 (https=)
JP (1) JP6997800B2 (https=)
CN (1) CN110869015B (https=)
AU (1) AU2018260535B2 (https=)
CA (1) CA3061296A1 (https=)
ES (1) ES2948767T3 (https=)
IL (2) IL251949A0 (https=)
WO (1) WO2018198123A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122202A1 (en) * 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
JP7481329B2 (ja) * 2018-06-07 2024-05-10 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
WO2020132045A1 (en) * 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023382A1 (en) * 1999-09-28 2001-04-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US20040039037A1 (en) * 2002-06-04 2004-02-26 Weijian Zhang Heterocyclic compounds and uses thereof
WO2008024302A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2013186777A2 (en) * 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY109202A (en) 1992-07-10 1996-12-31 Nihon Nohyaku Co Ltd Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
IT1313601B1 (it) 1999-08-05 2002-09-09 Isagro Ricerca Srl Fenilpirazoli ad attivita' erbicida
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
GB0306357D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
US20080249038A1 (en) 2003-10-07 2008-10-09 Quark Biotech, Inc. Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CN100396667C (zh) * 2006-02-20 2008-06-25 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp-2表达活性的五元不饱和杂环化合物
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
EP2453882A1 (en) * 2009-07-14 2012-05-23 Beth Israel Deaconess Medical Center, Inc. Methods of increasing liver proliferation
US20110039900A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
JP5725469B2 (ja) * 2010-11-15 2015-05-27 学校法人北里研究所 骨分化阻害剤およびその製造方法
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023382A1 (en) * 1999-09-28 2001-04-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US20040039037A1 (en) * 2002-06-04 2004-02-26 Weijian Zhang Heterocyclic compounds and uses thereof
WO2008024302A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2013186777A2 (en) * 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BOERGERMANN J.H. et al. "Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010) vol. 42, no. 11, 1 November 2010, pages 1802-1807 *
CHENG, X et al. "Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells", STEM CELLS (2007) vol. 25, no. 12, pages 3204-3214 *
DATABASE CAS Database accession no. 882268-63-5 CA Index Name: 2-Thiophenecarboxylic acid, 3-[2- [cyano(2-thienylsulfonyl)methylene]hydrazinyl]-, methyl ester; 30 April 2006 *
DATABASE CAS Database accession no. 882278-00-4 "2-Thiophenecarboxylic acid, 4- cyano-3-[2-[cyano(2-thienylsulfonyl)methylene]hydrazinyl]-, methyl ester" 30 April 2006 *
DATABASE PubChem Database accession no. CID 2820255 "Methyl 3-[2-[cyano(thiophen-2-ylsulfonyl) methylidene]hydrazinyl]thiophene-2-carboxylate", 19 July 2005 *
DATABASE PubChem Database accession no. CID 5715625"Methyl 3-[(2Z)-2-[cyano(thiophen-2-ylsulfonyl) methylidene]hydrazinyl]thiophene-2-carboxylate" 19 July 2005 *
DATABASE PubChem Database Accession no. CID 6371770 "Methyl 3-[(2E)-2-[cyano(thiophen-2-ylsulfonyl) methylidene]hydrazinyl]thiophene-2-carboxylate", 9 September 2005 *
DATABASE PubChem Database accession no. CID 6376145 "Methyl 4-cyano-3-[(2E)-2-[cyano(thiophen-2- ylsulfonyl)methylidene]hydrazinyl]thiophene-2-carboxylate", 11 September 2005 *
HONG C.C. et al "Applications of small molecule BMP inhibitors in physiology and disease", CYTOKINE & GROWTH FACTOR REVIEWS (2009) vol. 20, no. 5-6, 1 October 2009 *
SANVITALE C.E. et al. "A new class of small molecule inhibitor of BMP signaling", PLOS ONE (2013) vol. 8, no. 4 pages e62721 *

Also Published As

Publication number Publication date
CN110869015B (zh) 2023-08-18
IL269894B (en) 2022-03-01
US20210393582A1 (en) 2021-12-23
JP6997800B2 (ja) 2022-02-04
CA3061296A1 (en) 2018-11-01
EP3615022B1 (en) 2023-06-07
ES2948767T3 (es) 2023-09-18
EP3615022A4 (en) 2021-03-31
IL251949A0 (en) 2017-07-31
US11779565B2 (en) 2023-10-10
US11103479B2 (en) 2021-08-31
CN110869015A (zh) 2020-03-06
EP3615022C0 (en) 2023-06-07
AU2018260535A1 (en) 2019-10-31
US20200046680A1 (en) 2020-02-13
JP2020517678A (ja) 2020-06-18
EP3615022A1 (en) 2020-03-04
WO2018198123A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
KR101588464B1 (ko) 헌팅톤병 및 다계통 위축증을 치료하기 위한 ｍｉｐｏ 억제제
US11779565B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
KR102149321B1 (ko) Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
US20090227790A1 (en) Neuroprotective small organic molecules, compositions and uses of related thereto
JP7731868B2 (ja) ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
US20240208936A1 (en) Eaat2 activators and methods of using thereof
AU2021322329A1 (en) Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration
EP1734959A2 (en) Method of treating schizophrenia and/or glucoregulatory abnormalities
US11351229B2 (en) Combination therapies for treating infantile spasms and other treatment resistant epilepsies
US12492170B2 (en) Tetrahydro-1H-benzazepine compound as potassium channel modulator, preparation method and use thereof
US20200054578A1 (en) Lsd1 inhibitors as skeletal muscle hypertrophy inducers
Erringer et al. Chloroquine neuromyopathy associated with keratopathy and retinopathy
WO2013020909A1 (en) Materials and methods for the treatment of tauopathies
RU2846703C2 (ru) Композиции для предотвращения или лечения амиотрофии шарко-мари-тута (шмт)
KR20230083330A (ko) 운동 뉴런 질환 및 신경근 접합 장애 치료를 위한 N-(3-(4-(3-(다이이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민 황산염 및 이의 용매화물의 용도
AU2020359291B2 (en) Medicinal cognitive treatments
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途
HK40129651A (zh) 恶二唑衍生物化合物及包含其的药物组合物
JP2024506740A (ja) 脳損傷の治療

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)